Get the Stockscreener App
12.94
6.50%
0.79
After Hours:
12.95
0.010
+0.08%
Vor Biopharma Inc stock is traded at $12.94, with a volume of 680.85K.
It is up +6.50% in the last 24 hours and down -19.43% over the past month.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
See More
Previous Close:
$12.15
Open:
$12.3
24h Volume:
680.85K
Relative Volume:
0.73
Market Cap:
$537.27M
Revenue:
-
Net Income/Loss:
$-2.45B
P/E Ratio:
-0.0339
EPS:
-381.9068
Net Cash Flow:
$-144.67M
1W Performance:
-0.46%
1M Performance:
-19.43%
6M Performance:
-61.73%
1Y Performance:
-23.64%
1-Day Range:
$12.30
$13.17
1-Week Range:
$11.70
$13.78
52-Week Range:
$2.622
$65.80
Vor Biopharma Inc Stock (VOR) Company Profile
Name
Vor Biopharma Inc
Sector
Industry
Phone
617-655-6580
Address
500 BOYLSTON STREET, BOSTON
Compare VOR vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
12.94 | 504.47M | 0 | -2.45B | -144.67M | -381.91 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Vor Biopharma Inc Stock (VOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-19-26 | Initiated | Wells Fargo | Overweight |
| Jan-09-26 | Initiated | Citigroup | Buy |
| Dec-17-25 | Initiated | TD Cowen | Buy |
| Dec-09-25 | Initiated | JP Morgan | Overweight |
| Nov-25-25 | Resumed | Wedbush | Neutral |
| Oct-15-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-24-25 | Upgrade | Stifel | Hold → Buy |
| Jun-30-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-26-22 | Initiated | Wedbush | Outperform |
| Apr-27-22 | Initiated | Goldman | Neutral |
| Dec-17-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-21 | Initiated | Robert W. Baird | Outperform |
| Dec-02-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-21 | Initiated | JMP Securities | Mkt Outperform |
| Mar-25-21 | Initiated | B. Riley Securities | Buy |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Mar-03-21 | Initiated | Evercore ISI | Outperform |
| Mar-02-21 | Initiated | Goldman | Sell |
| Mar-02-21 | Initiated | Stifel | Buy |
View All
Vor Biopharma Inc Stock (VOR) Latest News
Profit Recap: What are analysts price targets for Vor Biopharma IncQuarterly Market Review & Growth Focused Stock Reports - baoquankhu1.vn
Vor Bio reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
8 new Vor Bio hires get stock awards tied to 261,935 shares - Stock Titan
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sahm
Vor Biopharma Inc.(NasdaqGS: VOR) added to S&P Biotechnology Select Industry Index - marketscreener.com
If You Invested $1,000 in Vor Biopharma Inc. (VOR) - Stock Titan
Short Covering: Should value investors consider Vor Biopharma Inc2026 Volatility Report & Long Hold Capital Preservation Tips - baoquankhu1.vn
RA CAPITAL MANAGEMENT, L.P. Increases Stake in Vor Biopharma Inc - GuruFocus
Wells Fargo initiates coverage of Vor Biopharma (VOR) with overweight recommendation - MSN
Wells Fargo Initiates Coverage on VOR with Overweight Rating | V - GuruFocus
Vor Biopharma (NASDAQ:VOR) Now Covered by Wells Fargo & Company - MarketBeat
Wells Fargo Initiates Vor Biopharma at Overweight With $30 Price Target - marketscreener.com
H.C. Wainwright Upgrades Vor Biopharma (VOR) to a Buy, Sets a $3 Price Target - MSN
RA Capital raises Vor Biopharma (VOR) reported beneficial stake to 19.9% - Stock Titan
Vor Biopharma Inc expected to post a loss of $1.64 a shareEarnings Preview - TradingView
Fcpm Iii Services B.V. Takes $18.50 Million Position in Vor Biopharma Inc. $VOR - MarketBeat
Vor Biopharma Inc. (NASDAQ:VOR) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
About Us | Oil & Gas JournalVor Biopharma Inc.Common Stock (Nasdaq:VOR) Stock Quote - FinancialContent
Guidance Update: Can Vor Biopharma Inc keep up with sector leadersTrade Exit Report & Reliable Breakout Forecasts - baoquankhu1.vn
Vor Biopharma Inc. (NASDAQ:VOR) Short Interest Up 24.5% in February - MarketBeat
VOR Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
VOR: Telitacicept advances in late-stage trials for MG and Sjögren's, targeting major autoimmune markets - TradingView
VOR Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Vor Bio to Participate in the 46th Annual TD Cowen Health Care Conference - GlobeNewswire
Pharma News: What are the analyst revisions for Vor Biopharma IncIs DMAC stock a good investment in YEARJuly 2025 Update & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Vor Biopharma Inc (VOR) Stock Price, Quote, News & History - Benzinga
[SCHEDULE 13G/A] Vor Biopharma Inc. Amended Passive Investment Disclosure - Stock Titan
Vor Bio Names Khan as Chief Medical Affairs Officer - Intellectia AI
Vor Bio Announces Inducement Grants in Compliance with Nasdaq Listing Rule 5635(c)(4) - Intellectia AI
Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
VOR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
VOR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Qiming funds disclose Vor Biopharma (VOR) common-stock holdings below 5% - Stock Titan
Vor Biopharma (NASDAQ:VOR) Stock Price Down 4%What's Next? - MarketBeat
Vor Biopharma Shares Skyrocket on Global Licensing Deal for Autoimmune Therapy - MSN
Exit Recap: Can Vor Biopharma Inc. keep up with sector leadersJuly 2025 Opening Moves & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
VOR Stock Unaffected by Selling Stockholders' Actions - GuruFocus
Is Vor Biopharma Inc. gaining market shareDollar Strength & Real-Time Stock Price Movement Reports - mfd.ru
Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Aug EndMonth: What is the PEG ratio of Vor Biopharma IncGap Down & High Conviction Trade Alerts - baoquankhu1.vn
Vor Biopharma Inc. (VOR) Presents at 44th Annual J.P. Morgan Healthcare ConferenceSlideshow - Seeking Alpha
VOR: TD Cowen Initiates Coverage with a 'Buy' Rating | VOR Stock News - GuruFocus
VOR: Telitacicept drives a global autoimmune strategy, backed by strong data, funding, and expert leadership - TradingView — Track All Markets
Form 8K Vor Biopharma Inc For: 12 January By Investing.com - Investing.com
Quarterly Risk: How Vor Biopharma Inc stock valuations compare to rivals2025 Retail Activity & Weekly Top Performers Watchlists - Bộ Nội Vụ
Vor Biopharma Inc. Common Stock (VOR) Stock Price Today & Analysis - Gotrade
Citigroup Initiates Coverage of Vor Biopharma (VOR) with Buy Recommendation - Nasdaq
Vor Biopharma (VOR) Receives New 'Buy' Rating From Citigroup | V - GuruFocus
Citigroup Begins Coverage on Vor Biopharma (NASDAQ:VOR) - MarketBeat
Citi Starts Vor Biopharma, Inc. (VOR) at Buy - StreetInsider
Vor Biopharma Inc Stock (VOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):